Clinical Research Studies
We look to you as our partners as we collectively learn more about SCN2A and its effects on patients and their families. We will regularly share new information and potential opportunities to get involved.
NOW ENROLLING IN THE UNITED STATES: SCN2A EEG Observational Study
We are currently enrolling for the SCN2A EEG Observational Study to collect information about children with early-onset SCN2A-DEE. This preliminary assessment of the condition could provide information that may facilitate later enrollment in EMBRAVE (PRAX-222).
Learn More
PLANNED STUDY:
EMBRAVE (PRAX-222)
EMBRAVE (PRAX-222) is specifically designed for early-onset children with gain-of-function SCN2A epilepsy. Those who participate in the SCN2A EEG Observational Study may be able to use some of the preliminary assessments as part of their eligibility evaluation. Stay tuned for more information.
Drug Development Programs
Praxis is currently developing potential new treatments for children with genetic epilepsies caused by gain-of-function mutations in SCN2A and SCN8A, as well as other indications.
Learn More
